Literature DB >> 23457315

Differentiated thyroid carcinoma in a girl with resistance to thyroid hormone management with triiodothyroacetic acid.

Agustín Ramos-Prol1, María Antonia Pérez-Lázaro, María Isabel del Olmo-García, Beatriz León-de Zayas, Francisca Moreno-Macián, Soledad Navas-de Solis, Juan Francisco Merino-Torres.   

Abstract

Thyroid hormone resistance syndrome is characterized by a reduced target tissue response to the action of thyroid hormone, which leads to high levels of free thyroxine and free triiodothyronine with non-suppressed levels of thyrotropin (TSH). Recently, three cases of papillary thyroid carcinoma associated with thyroid hormone resistance syndrome were published. The main challenge in this situation is the difficulty of maintaining the suppression of TSH levels without producing symptoms of hyperthyroidism. We present another case of an association of thyroid hormone resistance syndrome and papillary thyroid carcinoma, and we share our experience with 3,5,3'-triiodothyroacetic acid, which made possible an easier management of the carcinoma after surgery, maintaining the TSH levels suppressed despite the resistance to thyroid hormones.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23457315     DOI: 10.1515/jpem-2012-0230

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  5 in total

1.  Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature.

Authors:  João Vinagre; Fátima Borges; António Costa; Maria Inês Alvelos; Glaúcia Mazeto; Manuel Sobrinho-Simões; Paula Soares
Journal:  Front Mol Biosci       Date:  2014-09-02

2.  A novel mutation of thyroid hormone receptor β in exon 10 in a case of thyroid hormone-resistant non-Hodgkin's lymphoma of the thyroid.

Authors:  Ke Chen; Yanhong Xie; Liling Zhao; Shaoli Zhao; Honghui He; Zhaohui Mo
Journal:  Oncol Lett       Date:  2014-11-20       Impact factor: 2.967

3.  Coexistence of resistance to thyroid hormone and papillary thyroid carcinoma.

Authors:  Motoyuki Igata; Kaku Tsuruzoe; Junji Kawashima; Daisuke Kukidome; Tatsuya Kondo; Hiroyuki Motoshima; Seiya Shimoda; Noboru Furukawa; Takeshi Nishikawa; Nobuhiro Miyamura; Eiichi Araki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-03-30

4.  BRAFV600E mutation contributes papillary thyroid carcinoma and Hashimoto thyroiditis with resistance to thyroid hormone: A case report and literature review.

Authors:  Wanjia Xing; Xiaohong Liu; Qingqing He; Zongjing Zhang; Zhaoshun Jiang
Journal:  Oncol Lett       Date:  2017-06-28       Impact factor: 2.967

5.  Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Authors:  Xuguang Zhu; Li Zhao; Jeong Won Park; Mark C Willingham; Sheue-Yann Cheng
Journal:  Neoplasia       Date:  2014-09       Impact factor: 5.715

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.